Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions

Myeloma Multiple

Interventions

DRUG

Cyclophosphamide

Arm A

DRUG

Bortezomib (VELCADE)

Arm A, Arm B

DRUG

Dexamethasone

Arm A, Arm B

DRUG

Daratumumab-hyaluronidase

Arm B

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK